Characterisation of an influenza B variant selected with the neuraminidase inhibitor zanamivir

International Congress Series

Volumn 1263, Issue C, 2004, Pages 122-125

  Cheam, Ai Lee ^a,b   Barr, Ian ^a   Mosse, Jennifer ^b   Hampson, Alan ^a   Hurt, Aeron ^a  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

Author keywords

In vitro; Neuraminidase inhibitors; Oseltamivir; Zanamivir

Indexed keywords

EID: 84989208287     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.02.173     Document Type: Article

References (8)

1. McKimm-Breschkin, J.L., Resistance of influenza viruses to neuraminidase inhibitors—a review. Antivir. Res. 47 (2000), 1-17.
2. Barnett, J.M., et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 265 (1999), 286-295.
3. Staschke, K.A., et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214 (1995), 642-646.
4. Baum, E.Z., et al. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antivir. Res. 59 (2003), 13-22.
5. Gubareva, L.V., et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998), 1257-1262.
6. Hurt, A.C., et al. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Res., 2003 (in press).
7. Bantia, S, et al. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob. Agents Chemother. 42 (1998), 801-807.
8. Krystal, M, et al. Sequential mutations in hemagglutinins of influenza B virus isolates: definition of antigenic domains. Proc. Natl. Acad. Sci. U. S. A. 80 (1983), 4527-4531.